RE:RE:RE:RE:RE:ONCY pelareorep + CD3 bispecific antibody true-killer comboRepost from August 11, 2023 - FDA Approves J&J's Second Multiple Myeloma Bispecific Antibody
Johnson & Johnson took the fast track for its latest cancer drug. J&J’s subsidiary Janssen Pharmaceutical announced Thursday its bispecific antibody has won accelerated approval from the FDA for relapsed or refractory multiple myeloma.